UNSPSC 51161530: Amipizone

This classification denotes a phosphodiesterase inhibitor with the molecular formula C14H16ClN3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7OT95Q2G4E, chemically known as 6-(p-(2-chloropropionylamino)phenyl)-5-methyl-4,5-dihydropyridazin-3-one but generally known as amipizone, which bears US NIH Compound Identifier 68889. European Medicines Agency schedules Amipizone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05454MIG.

UNSPSC 51161530 Amipizone is a Commodity code covering pharmaceutical active ingredients and finished-dose formulations supplied to state and local government facilities. Recent state and local procurement under this code focuses on generic multi-source pharmaceuticals and over-the-counter (OTC) products distributed through authorized wholesaler networks to participating jurisdictions' healthcare and institutional settings. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary issuing body represented in recent activity. Vendors must be manufacturers or authorized distributors capable of supplying products with specific National Drug Codes (NDCs), meeting current Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) compliance, maintaining contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC), and providing comprehensive insurance including commercial general liability of $5 million per occurrence and network security and privacy liability of $2 million.

Minnesota and Oregon are the primary states served under MMCAP's recent cooperative purchasing activity. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 on January 20, 2026, with a response deadline of March 26, 2026, seeking multiple contract awards for generic pharmaceuticals and OTC products effective July 1, 2026. Evaluation weighting emphasizes price competitiveness (75 percent), with fixed pricing, compliance with data format requirements, electronic data interchange (EDI) capability, and agreement to a 3 percent administrative fee each receiving smaller weights. Vendors must provide pricing flexibility through flat price, net price formats (NF30, NF60, NF90), or WAC-minus structures, and all products require FDA compliance, expiration dates of at least one year from manufacture, and a minimum six-month shelf life. Contract terms span two years for new respondents with optional MMCAP extensions, or alignment with incumbent agreement expiration dates through June 30, 2028.